• Earlier this month, Regeneron Pharmaceuticals announced that the FDA approved extending EYLEA HD dosing intervals up to 20 weeks for certain wet age-related macular degeneration and diabetic macular edema patients, updating the label with 96-week efficacy and safety data from the PULSAR and PHOTON trials.
• This change materially lowers treatment burden for eligible patients while broadening the drug’s flexibility versus other injectable anti-VEGF options, potentially reinforcing EYLEA HD’s position in retinal care.
• We’ll now examine how this extended 20-week dosing flexibility for EYLEA HD reshapes Regeneron’s investment narrative and long-term growth profile.

Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Regeneron Pharmaceuticals Investment Narrative Recap

To own Regeneron, you need to be comfortable with a business still heavily anchored to EYLEA while it invests aggressively in a broader pipeline. The new 20 week EYLEA HD dosing approval directly supports the near term catalyst of defending the retinal franchise against competition, but it does not remove the key risk of pricing and share pressure in anti VEGF or the company’s reliance on a few major products.

Among recent developments, the planned US FDA decision in April 2026 on the EYLEA HD prefilled syringe stands out as particularly relevant. If approved, it could complement the extended dosing label by simplifying administration and potentially supporting physician adoption, which matters as Regeneron balances EYLEA headwinds with other growth drivers like Dupixent and newer oncology and hematology assets.

Yet, even with these positives, there is an important pricing and biosimilar risk around EYLEA that investors should be aware of...

Regeneron Pharmaceuticals' narrative projects $18.7 billion revenue and $6.0 billion earnings by 2029. This requires 9.2% yearly revenue growth and about a $1.5 billion earnings increase from $4.5 billion today.

Uncover how Regeneron Pharmaceuticals' forecasts yield a $873.78 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling around US$21.0 billion in revenue and US$7.4 billion in earnings by 2029, so if you believe EYLEA HD’s new label could blunt biosimilar and pricing pressure more than consensus expects, your view may sit much closer to that bullish camp than to the more cautious baseline.

Explore 9 other fair value estimates on Regeneron Pharmaceuticals - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Regeneron Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Regeneron Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Regeneron Pharmaceuticals' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find 58 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.